In the present issue, two studies highlight the role of rehabilitation, secondary prevention and long-term follow-up of cardiovascular patients, also after an invasive procedure: in particular after catheter ablation for persistent atrial fibrillation (AF) and in peripheral artery disease (PAD) patients.
Cardiac rehabilitation after catheter ablation for persistent AF
AF is the most frequent arrhythmia in the general population and is not only associated with significant morbidity and mortality but it also adversely impacts quality of life. 1 A small group of patients with persistent AF were randomly assigned to the intervention of catheter ablation alone versus catheter ablation plus a cardiac rehabilitation programme that included endurance and resistance training at least three times per week. After 6 months, only those patients who underwent a rehabilitation programme significantly improved exercise capacity and their systemic inflammatory status, associated with improvement in echocardiographic parameters.
Follow-up after revascularisation for PAD
A consensus document from the European Society of Cardiology (ESC) working group on aorta and peripheral vascular diseases and the European Society for Vascular Surgery provides recommendations about the long-term follow-up of patients with PAD. Multiple studies have shown that secondary prevention after PAD is as crucial as after an acute coronary syndrome. However, one important gap in the guidelines for myocardial revascularisation and in the European guidelines for the diagnosis and treatment of PAD is exactly the secondary prevention and follow-up of these patients. 2 The focus must be on the long-term maintenance of a healthy lifestyle and compliance with medication, nutritional and exercise recommendations.
Breakdown of the levels of evidence supporting the ESC guidelines
In recent years cardiovascular guidelines have increasingly been criticised for the limited amount of evidence underlying many of their recommendations. 3 Evidence levels supporting guidelines give insights into the status of the cardiovascular evidence base at a given time. When the guidelines have been broken down into their fields of application (e.g. pharmaceutical or surgical interventions, diagnostic, prognostic stratification), it has been observed that pharmaceutical interventions are traditionally found to be more grounded in level A evidence than other recommendations. The role of investments in new drugs is evident. Trials also have remained laborious and become increasingly expensive, barely innovating in their execution, limiting their numbers and leaving clinicians and guideline authors to rely on lower levels of evidence as a result. In the present issue encouraging information comes from a review of the recently released 2019 guidelines of the ESC which has shown that the number of recommendations supported by the highest level of evidence A has increased from 24.4% to 38.2%, while the number of recommendations supported by lower levels of evidence B and C has been reduced. However these percentages still highlight the need for innovation in trials to decrease their costs to allow them to add knowledge on evidence gaps where profitable business cases are lacking.
Determination of the intensity of exercise training in cardiovascular rehabilitation
A barrier in implementation of exercise training in clinical practice has been attributed to the presence of inconsistencies and discrepancies between different recommendations regarding the most appropriate modality of training programme in cardiovascular rehabilitation. 4 Here the most effective modality of exercise training has been explored and the different intensities currently recommended have been compared. Patients undergoing cardiovascular rehabilitation performed cardiopulmonary exercise testing in order to compute the first (VT1) and the second anaerobic threshold (VT2) and to compare different recommended levels of exercise intensity. The authors compared the elicited exercise responses at VT1 and VT2 (expressed as %VO 2peak , %HR peak , %W peak and %heart rate reserve) with the guideline-based exercise intensity domains for cardiovascular rehabilitation. The results confirmed the presence of discrepancies between different recommendations.
When searching for the best method to determine exercise intensity we have also to keep in mind that this approach has to be easily measured, reproducible and with low cost. While the best way to determine exercise intensity is still to be found we have to reach a consensus on the best available parameters so far for exercise intensity definition.
Hyperlipidaemia in relation to the Mediterranean diet
Based on the Hellenic Nutrition and Health Survey, in 3775 adults, the prevalence and awareness of dyslipidaemia, blood lipid status and treatment were analysed. About 21% of the population was reported as having hyperlipidaemia and only 59% of them were receiving treatment. However, only 46.6% of the treated people had a normal lipid profile and were considered as being controlled. Finally, almost two-thirds of the population was unaware of their lipid status, showing that there is still room for an appropriate project to raise awareness in the population and their general practitioners on the opportunity to control their blood lipids. The study confirmed a direct relation between lipid status and overweight/obesity and that the lipid-lowering effects of the Mediterranean diet are not as pronounced as expected. 5
CHA 2 DS 2 -VASc score use in sinus rhythm
The CHA 2 DS 2 -VASc score was developed to stratify patients with AF with regard to the risk of thromboembolism. Higher scores have also recently been associated with increased mortality in patients with AF and recent studies have investigated this association further in patients without AF. In the present issue, the CHA 2 DS 2 -VASc score was used in 22,179 middleaged individuals with 18,367 in sinus rhythm, to assess its prognostic yield in the non-AF population. It confirmed the predictive role of the CHA 2 DS 2 -VASc score for new onset AF. Moreover, the cumulative incidence of AF was greater with increasing CHA 2 DS 2 -VASc strata, allowing a simple and rapid assessment of thromboembolic risk according to the presence of a number of risk factors. Furthermore, this score enabled mortality and cardiovascular risk stratification in non-AF middle-aged adults. A CHA 2 DS 2 -VASc score of 4 or greater in non-AF individuals was associated with a 5-year absolute risk of ischaemic stroke similar to a CHA 2 DS 2 -VASc score of 2 in AF individuals. A CHA 2 DS 2 -VASc score of 4 heralded an ischaemic stroke rate greater than 0.9% per year among non-AF individuals, matching a previously proposed threshold for the safe prescription of nonvitamin K oral anticoagulants in patients with AF. An important limitation of the present study was the lack of precise information on the characteristics of AF and concomitant comorbidities. 6 The developing athlete's heart Athlete's heart is a term used to describe physiological changes in the hearts of athletes, 7,8 but its early development has not been described in longitudinal studies.
Here cardiac morphology and function in 48 crosscountry skiers were assessed at age 12 years (12.1 AE 0.2 years) and then again at age 15 years (15.3 AE 0.3 years) when 31 (65%) were still active endurance athletes. All subjects underwent echocardiography examination as well as cardiopulmonary exercise testing. It was observed that after an initial concentric remodelling in the pre-adolescent athletes, only those who continued their endurance training developed eccentric changes with chamber dilation and little change in wall thickness. Those who ceased endurance training maintained a comparable wall thickness, but did not develop chamber dilation.
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